- Center for Neurology
- brain tumors
- single-cell & spatial multi-omics
- epigenetic reprogramming
Schwartz AV, Chao G, Robinson M, Conley BM, Ahmed Adam MA, Wells GA, Hoang A, Albekioni E, Gallo C, Weeks J, Yunker K, Quichocho G, George UZ, Niesman I, House CD, Turcan Ş*, Sohl CD* (2025). Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models. J Biol Chem. May;301(5):108477
Blanco-Carmona E, Narayanan A, Hernandez I, Nieto JC, Elosua-Bayes M, Sun X, Schmidt C, Pamir N, Özduman K, Herold-Mende C, Pagani F, Cominelli M, Taranda J, Wick W, von Deimling A, Poliani PL, Rehli M, Schlesner M, Heyn H, Turcan Ş (2023). Tumor heterogeneity and tumor-microglia interactions in IDH mutant gliomas. Cell Rep Med. Nov 21;4(11):101249.
Demirdizen E, Al-Ali R, Narayanan A, Sun X, Varga JP, Steffl B, Brom M, Krunic D, Schmidt C, Schmidt G, Bestvater F, Taranda J, Turcan Ş* (2023). TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing. Neuro Oncol. Jun 2;25(6):1031-1043.
Turcan S#, Makarov V, Taranda J, Wang Y, El-Amine N, Haddock S, Nanjangud G, LeKaye CH, Brennan C, Cross J, Huse JT, Kelleher NL, Osten P, Thompson CB, Chan TA#. Mutant IDH1-dependent chromatin state reprogramming, reversibility, and persistence (2018). Nature Genetics 2018 Jan;50(1):62-72